辅助对流增强递送治疗脑肿瘤
本文综述对流增强递送(CED)治疗恶性胶质瘤的文献,总结基于不同生物学机制和技术创新的临床试验,讨论其特性、特征、里程碑试验及未来趋势,认为CED疗效迄今参差不齐,但技术和治疗剂的改进有前景。
要点
- 恶性胶质瘤治疗困难且几乎均致命,新型靶向药物尚未转化为成功临床治疗。
- 常规递送方式(血管内、脑脊液、聚合物植入)对恶性胶质瘤细胞分布不佳。
- CED疗效迄今参差不齐,但技术和治疗剂的改进有前景。
核心结论
- CED治疗恶性胶质瘤的疗效迄今参差不齐,但技术和治疗剂的改进有前景。
研究设计与样本
- 作者对文献进行综述,检索词为「对流增强递送」「胶质母细胞瘤」和「胶质瘤」,基于不同生物学机制和技术创新总结部分临床试验,尽可能聚焦较新发表的数据。
主要发现
- 描述了与恶性胶质瘤对流增强递送相关的特性、特征和里程碑临床试验。
- 讨论了对未来CED创新和改进至关重要的未来趋势。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Malignant gliomas are a therapeutic challenge and remain nearly uniformly fatal. While new targeted chemotherapeutic agentsagainst malignant glioma have been developed in vitro, these putative therapeutics have not been translated into successful clinical treatments. The lack of clinical effectiveness can be the result of ineffective biologic strategies, heterogeneous tumor targets and/or the result of poortherapeutic distribution to malignant glioma cells using conventional nervous system delivery modalities (intravascular, cerebrospinal fluid and/orpolymer implantation), and/or ineffective biologic strategies. METHODS: The authors performed a review of the literature for the terms "convection enhanced delivery", "glioblastoma", and "glioma". Selectclinical trials were summarized based on their various biological mechanisms and technological innovation, focusing on more recently publisheddata when possible. RESULTS: We describe the properties, features and landmark clinical trials associated with convection-enhanced delivery for malignant gliomas.We also discuss future trends that will be vital to CED innovation and improvement. CONCLUSION: Efficacy of CED for malignant glioma to date has been mixed, but improvements in technology and therapeutic agents arepromising.
引用
- Kreatsoulas D, Damante M, Cua S, et al. Adjuvant convection-enhanced delivery for the treatment of brain tumors. J Neurooncol. 2024. PMID: 38261143. doi:10.1007/s11060-023-04552-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。